.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,735,450

« Back to Dashboard

Details for Patent: 8,735,450

Title:Formulation of diclofenac
Abstract: The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.
Inventor(s): Dodd; Aaron (Centennial Park, AU), Meiser; Felix (Mount Claremont, AU), Norret; Marck (Darlington, AU), Russell; Adrian (Rivervale, AU), Bosch; H William (Bryn Mawr, PA)
Assignee: Iceutica Pty Ltd. (Philadelphia, PA)
Filing Date:Apr 23, 2010
Application Number:13/266,122
Claims:1. A method for producing a composition comprising nanoparticles of diclofenac acid, comprising: dry milling a composition comprising diclofenac acid, lactose and sodium lauryl sulfate in a mill containing a plurality of milling bodies for a time period sufficient to produce a composition comprising nanoparticles of diclofenac acid having a median particle size on a particle volume basis between 1,000 nm and 25 nm; and processing the composition comprising nanoparticles of diclofenac acid into a unit dosage pharmaceutical composition containing 18 mg of diclofenac acid, wherein the unit dosage pharmaceutical composition, when tested in vitro by USP Apparatus I (Basket) method of U.S. Pharmacopoeia at 100 rpm at 37 .degree.C. in 900 ml of 0.05% sodium lauryl sulfate in citric acid solution buffered to pH 5.75, has a dissolution rate of diclofenac acid such that at least 91%, by weight, is released by 45 minutes.

2. The method of claim 1 wherein the processing comprises combining the composition comprising nanoparticles of diclofenac acid with at least one pharmaceutically acceptable excipient or carrier.

3. The method of claim 2 wherein the processing comprises combining the composition comprising nanoparticles of diclofenac acid with microcrystalline cellulose, croscarmellose sodium, and sodium stearyl fumarate.

4. The method of claim 1 wherein the unit dosage pharmaceutical composition comprises a hard gelatin capsule.

5. The method of claim 1 or 4 wherein the unit dosage pharmaceutical composition has a dissolution rate of diclofenac acid such that at least 91%, by weight, is released by 30 minutes.

6. The method of claim 1 or 4 wherein the unit dosage pharmaceutical composition has a dissolution rate of diclofenac acid such that at least 91%, by weight, is released by 15 minutes.

7. The method of claim 1 or 4 wherein the unit dosage pharmaceutical composition has a dissolution rate of diclofenac acid such that at least 94%, by weight, is released by 45 minutes.

8. The method of claim 1 or 4 wherein the unit dosage pharmaceutical composition has a dissolution rate of diclofenac acid such that at least 94%, by weight, is released by 30 minutes.

9. The method of claim 1 wherein the unit dosage pharmaceutical composition is a filled capsule.

10. A method for producing a composition comprising nanoparticles of diclofenac acid, comprising: dry milling a composition comprising diclofenac acid, lactose and sodium lauryl sulfate in a mill containing a plurality of milling bodies for a time period sufficient to produce a composition comprising nanoparticles of diclofenac acid having a median particle size on a particle volume basis between 1,000 nm and 25 nm; and processing the composition comprising nanoparticles of diclofenac acid into a unit dosage pharmaceutical composition containing 35 mg of diclofenac acid, wherein the unit dosage pharmaceutical composition, when tested in vitro by USP Apparatus I (Basket) method of U.S. Pharmacopoeia at 100 rpm at 37 .degree.C. in 900 ml of 0.05% sodium lauryl sulfate in citric acid solution buffered to pH 5.75, has a dissolution rate of diclofenac acid such that at least 82%, by weight, is released by 45 minutes.

11. The method of claim 10 wherein the processing comprises combining the composition comprising nanoparticles of diclofenac acid with at least one pharmaceutically acceptable excipient or carrier.

12. The method of claim 11 wherein the processing comprises combining the composition comprising nanoparticles of diclofenac acid with microcrystalline cellulose, crosscarmellose sodium, and sodium stearyl fumarate.

13. The method of claim 10 wherein the unit dosage pharmaceutical composition comprises a hard gelatin capsule.

14. The method of claim 10 or 13 wherein the unit dosage pharmaceutical composition has a dissolution rate of diclofenac acid such that at least 82%, by weight, is released by 30 minutes.

15. The method of claim 10 or 13 wherein the unit dosage pharmaceutical composition has a dissolution rate of diclofenac acid such that at least 82%, by weight, is released by 15 minutes.

16. The method of claim 10 or 13 wherein the unit dosage pharmaceutical composition has a dissolution rate of diclofenac acid such that at least 95%, by weight, is released by 45 minutes.

17. The method of claim 10 or 13 wherein the unit dosage pharmaceutical composition has a dissolution rate of diclofenac acid such that at least 95%, by weight, is released by 30 minutes.

18. The method of claim 10 wherein the unit dosage pharmaceutical composition is a filled capsule.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc